Dr. Weihan Liu is an Associate at Cure Ventures, with over ten years of experience in biomedical research. Most recently, Weihan was a consultant at ClearView Healthcare Partners, where he worked with pharma and biotech companies to address critical challenges in drug development and commercialization. Prior to that, he earned his Ph.D. at the University of Chicago, where he discovered a fundamental mechanism of early hematopoietic stem cell fate commitment via epigenetic remodelling. His research experience also includes time at Dana-Farber Cancer Institute, identifying breast cancer drug resistance mechanisms, and at Genentech, where he investigated novel therapeutic targets for aggressive cancers with no effective therapies. These experiences deepened his passion to find cures for diseases with high unmet needs.
Beyond research, Weihan gained life science translational experience as an intern with ARCH Venture Partners and the University of Chicago’s George Schulz Innovation Fund. There, he sourced promising technologies, evaluated scientific and clinical data, and broadened his understanding of diseases like obesity, autoimmune disorders, and mental health etc.
Weihan holds a Ph.D. in Cancer Biology from the University of Chicago, where he trained under Dr. Megan McNerney, and a B.A. in Molecular Biology from the University of California, Berkeley. Joining Cure Ventures represents an exciting transition for Weihan to apply his knowledge to help derisk promising science and translate groundbreaking cures from the bench to the bedside.